

## CSIM Virtual Workshops 2026 Evidence of Conflict of Financial Interest

### Planning Committee

Last Name	First Name	Declaration
<b>Blois</b>	Willem	No conflicts to declare
<b>Chisick</b>	Laura	No conflicts to declare
<b>Duke</b>	Stephen	No conflicts to declare
<b>Gregory</b>	Peter	No conflicts to declare
<b>Iqbal</b>	Sahar	Direct financial payments/honoraria: Montreal Heart Institute. Membership on advisory boards or speakers' bureaus: Novo Nordisk, Eli Lilly, Abbott, Astra Zeneca, Sanofi, Medtronic. Funded grants or clinical trials: Novo - FLOW, ONWARDS5, Eli Lilly TRIUMPH
<b>LindenSmith</b>	Jorin	No conflicts to declare
<b>MacGregor</b>	Jenna	No conflicts to declare
<b>Mahone</b>	Michèle	No conflicts to declare
<b>Meng</b>	Ziran	No conflicts to declare
<b>Ratushny</b>	Jeff	No conflicts to declare
<b>Schaefer</b>	Jeff	Direct financial payments/honoraria: Pfizer, Novo-Nordisk
<b>Shadowitz</b>	Steven	No conflicts to declare
<b>Tagalakis</b>	Vicky	No conflicts to declare
<b>Tran</b>	Allen	Direct financial payments/honoraria: Abbvie. Funded grants or clinical trials: Royal College of Physicians and Surgeons of Canada; Canadian Society of Internal Medicine.

## Faculty

Last Name	First Name	Declaration
<b>Brothers</b>	Thomas	Funded grants or clinical trials: Canadian Institutes of Health Research; Research Nova Scotia; Canadian Research Initiative in Substance Matters; Dalhousie University Internal Medicine Research Foundation. This speaker intends to make off-label use recommendations: Slow-release oral morphine (SROM; Kadian) is off-label treatment for opioid use disorder and recommended as second-line treatment in our national guidelines
<b>Chambers</b>	Heather	No conflicts to declare
<b>Dubrofsky</b>	Lisa	No conflicts to declare
<b>Iatan</b>	Iulia	Direct financial payments/honoraria: Amgen, Novartis, Ultragenyx, Merck Membership on advisory boards or speakers' bureaus: Novartis, Amgen, Ultragenyx
<b>Purdy</b>	Kerri	Direct financial payments/honoraria: Abbvie, Arcutis, Bausch Health, Eli Lilly, Incyte, Janssen, Leo pharma, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, UCB. Membership on advisory boards or speakers' bureaus: Abbvie, Amgen, Arcutis, Bausch Health, Eli Lilly, Incyte, Janssen, Leo pharma, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, UCB. Funded grants or clinical trials: Abbvie, Amgen, Sanofi Genzyme. This speaker intends to make off-label use recommendations: some treatments are off label for serious drug eruptions.
<b>Tarlton</b>	Caitlin	Direct financial payments/honoraria: Virtual Hallway. Membership on advisory boards or speakers' bureaus: Roche, Novartis, Amgen Horizon, EMD Serono, Biogen. Funded grants or clinical trials: Roche, Novartis. This speaker intends to make off-label use recommendations as the majority of proposed preventative treatments for autoimmune encephalitis are off-label given rarity of conditions and lack of randomized control trials leading to Health Canada
<b>Tran</b>	Karen	No conflicts to declare

*At December 15, 2025*